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Abstract
Diabetic conditions are associated with modified brain function, namely with cognitive deficits, through largely
undetermined processes. More than understanding the underlying mechanism, it is important to devise novel strategies to
alleviate diabetes-induced cognitive deficits. Caffeine (a mixed antagonist of adenosine A1 and A2A receptors) emerges as a
promising candidate since caffeine consumption reduces the risk of diabetes and effectively prevents memory deficits
caused by different noxious stimuli. Thus, we took advantage of a novel animal model of type 2 diabetes to investigate the
behavioural, neurochemical and morphological modifications present in the hippocampus and tested if caffeine
consumption might prevent these changes. We used a model closely mimicking the human type 2 diabetes condition,
NONcNZO10/LtJ mice, which become diabetic at 7–11 months when kept under an 11% fat diet. Caffeine (1 g/l) was
applied in the drinking water from 7 months onwards. Diabetic mice displayed a decreased spontaneous alternation in the
Y-maze accompanied by a decreased density of nerve terminal markers (synaptophysin, SNAP25), mainly glutamatergic
(vesicular glutamate transporters), and increased astrogliosis (GFAP immunoreactivity) compared to their wild type
littermates kept under the same diet. Furthermore, diabetic mice displayed up-regulated A2A receptors and down-regulated
A1 receptors in the hippocampus. Caffeine consumption restored memory performance and abrogated the diabetes-
induced loss of nerve terminals and astrogliosis. These results provide the first evidence that type 2 diabetic mice display a
loss of nerve terminal markers and astrogliosis, which is associated with memory impairment; furthermore, caffeine
consumption prevents synaptic dysfunction and astrogliosis as well as memory impairment in type 2 diabetes.
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Introduction
Reduced peripheral glucose regulation and diabetic conditions
affect the central nervous system, contributing to diabetic
encephalopathy [1]. In particular, diabetic individuals display an
augmented incidence of cognitive problems, which are particularly
associated with atrophy of the hippocampal formation, which is
involved in learning and memory processing [2,3]. However, the
mechanisms underlying the development of diabetic encephalop-
athy and associated cognitive impairments remain unknown.
The prevention of neuronal dysfunction and neurodegeneration
represents a major goal of medical research, and an emerging
candidate to manage diabetes-induced neurodegeneration is
caffeine [4]. Caffeine is the most widely consumed psychoactive
substance and acts as an antagonist of adenosine A1 receptors
(A1R) and A2AR at non-toxic doses [5]. Caffeine consumption
alleviates cognitive impairment in both humans and animals [6,7],
namely in Alzheimer’s disease [8–10], and affords protection upon
CNS injury [11,12]. Furthermore, several studies indicate that
habitual coffee consumption reduces the risk of diabetes [13].
Conversely, we found that streptozotocin-induced diabetes
modifies the expression and density of adenosine receptors in the
hippocampus [14], as occurs in most noxious brain conditions [11]
and caffeine prevents streptozotocin-induced neurotoxicity
[15,16]. Thus, we hypothesize that chronic caffeine treatment
could prevent the alterations of neuropathology and function
associated with the hippocampus known to occur in type 2
diabetes.
We now took advantage of a new mouse strain modelling type 2
diabetes, NONcNZO10/LtJ mice [17], to test if chronic caffeine
consumption prevents the diabetes-induced molecular and mor-
phological alterations in the hippocampus. NONcNZO10/LtJ
mice are a recombinant congenic strain generated by combining
trait loci from New Zealand Obese (NZO/HlLt) and non-obese
non-diabetic (NON/LtJ) mice [18]; NONcNZO10/LtJ mice
display maturity onset obesity (after 13 weeks, under higher fat
diets) associated with a diabetes phenotype characterised by mild
hyperglycemia and insulin resistance in skeletal muscle, liver and
heart [17,18]; the polygenic nature and the relatively mild obesity
of this model closely resemble human type 2 diabetes, thus making
it an attractive model to investigate modifications of brain
morphology and function and to test if caffeine might indeed
affect diabetes-associated brain dysfunction. We obtained the first
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markers, namely of glutamatergic markers, together with an
evident astrogliosis, which are associated with a decreased short-
term memory performance. Further re-enforcing this association
between synaptotoxicity and astrogliosis with memory impair-
ment, we found that the prolonged consumption of caffeine
abrogated the diabetes-induced synaptotoxicity and astrogliosis
and preserved memory function.
Materials and Methods
Ethics Statement
All animals used in the study were handled according to EU
guidelines (86/609/EEC); all mice were deeply anesthetized under
halothane atmosphere before sacrifice by decapitation. The
experiments were approved by the Center’s Ethics committee
(Comissa ˜o de Instalac ¸a ˜o do Biote ´rio FMUC-CNC; permit issued
on 7
th September 2007).
Animals and Caffeine Treatment
Male NONcNZO10/LtJ mice and control NON/LtJ mice
( Jackson Laboratory, Bar Harbor, Maine, USA) were maintained
under an 11% fat diet from the age of 7 months onwards. Half of
the mice from each group were randomly selected for treatment
with 1 g/L caffeine (Sigma-Aldrich, Sintra, Portugal) supplied in
the drinking water during 20 weeks (from 30 to 50 weeks of age).
This dose of caffeine was selected based on its previously reported
ability to prevent memory impairment and modifications of
hippocampal synaptic proteins in other animal models of brain
disorders [15,19]. It corresponds to a high intake of caffeine,
leading to a concentration of caffeine in the plasma and brain
parenchyma similar to that expected to occur in humans
consuming 8 cups of coffee daily [20]. This high intake of caffeine
was chosen also because it is such a high intake, rather than low or
moderate intake, of coffee that attenuate the burden of diabetes
[13]. Weight and water/caffeine consumption were monitored
during the treatment and pre-prandial glycaemia was measured
monthly from tail blood [14,15]. Therefore, 4 groups of mice were
used throughout the study: control NON/LtJ mice (10 animals),
control NON/LtJ mice treated with caffeine (10 animals), diabetic
NONcNZO10/LtJ mice (10 animals), diabetic NONcNZO10/LtJ
mice treated with caffeine (9 animals). Mice in the control and
diabetic groups were randomly assigned to consume either water
or caffeine before beginning of the study. All these animals were
used for general characterization (see Table 1) and behavioural
assays and, within each group, 4 mice were used for immunohis-
tochemical analysis and 5–6 different mice were used for
immunocytochemical and neurochemical analysis.
Quantification of Serum Insulin and Caffeine
At the end of the 20-week caffeine treatment, plasma insulin
concentration was quantified by enzyme immunoassay [14,15].
Serum caffeine concentration was evaluated, as previously
described [15], by HPLC using a reverse-phase column [LiChro-
CART 12564 mm LiChrospher 100 RP-18 (5 mm) cartridge
fitted into a ManuCART holder (Merck, Darmstadt, Germany)]
and a Gilson system equipped with a UV detector set at 274 nm.
The eluent was 40% (v/v) methanol with a flow rate of 0.8 mL/
min. Identification and quantification of caffeine was performed
by comparison of relative retention time with standards (1–
100 mM).
Behavioural Tasks
Locomotor activity was determined using an open field arena
after habituation [10,15]. Spontaneous alternation was assessed in
a Y-maze to access hippocampal-dependent memory, constituting
a basic mneumonic task, which does not involve an evident
‘learning’ component and does not isolate memory performance
but is a robust predictor of short term memory performance
[10,15,19]. The total number of entries in the arms of the Y maze
also allows accessing locomotor activity and exploratory behav-
iour. All the mice were run in the Y maze before the initiation of
the treatments (high fat or caffeine or respective controls) and then
tested again after the 4 month treatment, the day after the open
field test. Clearly, the use of a single behavioural 1 day paradigm
only allows a rough estimate of short memory performance;
however, previous studies from our group using rodent models of
Alzheimer’s disease have shown that the Y maze test has sufficient
sensitivity to highlight insidious changes of memory performance
(see [10,21]), with the great advantage of being devoid of
conditioning or aversive components. Never the less, it should
be made clear that this experimental design is only intended to
provide evidence for the existence of putative impairments of short
term memory performance rather than allowing to define if such
deficits also occur for long term memory and if they result from
memory formation, consolidation or retrieval.
Immunocytochemical Analysis in Hippocampal Nerve
Terminals
Hippocampal nerve terminals were purified through a discon-
tinuous Percoll gradient and platted over poly-L-lysine-coated
cover-slips for immunocytochemical analysis, using antibodies that
were previously validated [22,23]. Permeabilized nerve terminals
were incubated for 1 hour with mouse anti-synaptophysin (1:200,
Sigma-Aldrich), rabbit anti-A1R (1:200, Affinity Bioreagent,
Rockford, IL, USA) or goat anti-A2AR (1:200, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), and guinea pig anti-
vesicular GABA transporters (vGAT, 1:1000, Calbiochem, San
Diego, CA, USA) or guinea pig anti-vesicular glutamate
transporters (vGluT1) plus guinea pig anti-vGluT2 (both 1:1000,
Chemicon, Temecula, CA, USA) followed by a 1 hour incubation
with AlexaFluor-labelled secondary antibodies (1:2000, Molecular
Probes, Leiden, The Netherlands), which did not yield any signal
in the absence of the corresponding primary antibodies. After
washing and mounting onto slides with Prolong Gold Antifading
(Invitrogen, Eugene, OR, USA), preparations were visualized in a
Zeiss fluorescence microscope equipped with a cooled CCD
camera and analyzed with MetaFluor 5.0 software [22]. Each
coverslip was analyzed by counting three different fields and in
each field a total amount of 500 individualized elements, as
previously described [23].
Western Blot Analysis in Hippocampal Membranes
Western blot analysis was carried out as previously described
[10,14,15,19,23] using antibodies against A1R (dilution 1:600),
synaptophysin (1:2000, Sigma-Aldrich), SNAP25 (1:2000, Sigma-
Aldrich), vGluT1 (1:5000, Chemicon), vGAT (1:1000, Calbio-
chem), PSD95 (1:2000, Upstate Biotechnology, Lake Placid, NY,
USA), gephyrin (1:500, Abcam, Cambridge, UK), MAP2 (1:200,
Santa Cruz Biotechnology) or GFAP (1:1000, Sigma-Aldrich). The
membranes were then re-probed and tested for a-tubulin
immunoreactivity to confirm that similar amounts of protein were
applied to the gels [10,14,15,19,23].
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The density of A1Rs and A2ARs in synaptosomal membranes
from the hippocampus was determined using supra-maximal
concentrations (6 nM) of either the selective A1R antagonist,
3H-
DPCPX (specific activity of 109.0 Ci/mmol, DuPont NEN,
Boston, MA, USA), or the selective A2AR antagonist,
3H-SCH
58261 (specific activity of 77 Ci/mmol; prepared by Amersham
and offered by Dr. E.Ongini, Shering-Plough, Italy), following
procedures previously described [14].
Mouse Brain Histochemistry
The preparation of brain coronal sections (20 mm) was carried
out as previously described, after perfusion–fixation with 4%
paraformaldehyde in 0.15 mM sodium phosphate buffer, pH 7.4
(for 6 hours) under deep pentobarbital anaesthesia (50 ml/kg, i.p.),
followed by a 24 hours post-fixation in the same fixative solution
[10,15]. Neuronal hippocampal morphology was assessed using a
cresyl violet staining of Nissl bodies and FluoroJade-C staining was
used to evaluate neuronal degeneration and immunohistochemical
analysis of dendritic processes [MAP2 staining (1:500)], of
astrocytes [GFAP staining using a Cy3-conjugated anti-GFAP
mouse monoclonal antibody (1:1000, Sigma-Aldrich)] and of
nerve terminals [synaptophysin staining (1:500)] was carried out as
previously described [10,15]. After mounting (Vectashield H-
1400, Vector Laboratories, Baptista Marques, Lisbon, Portugal),
brain slices were examined under an Axiovert 200 Zeiss
fluorescence microscope and digital photomicrographs were
obtained at a magnification of either 406or 636(oil-immersion
lens, numerical aperture of 1.3), with a cooled CCD digital
camera, adjusted to these parameters. Images were processed and
analysed with the software ImageJ 1.37v (NIH, Bethesda, MD,
USA); data from cresyl violet staining was only evaluated
qualitatively, whereas the number of degenerated neurons (stained
with FluoroJadeC) or the integral of fluorescence (MAP-2, GFAP
or synaptophysin staining) were counted in at least 3 regions with
50650 mm in each section in at least 3 sections per animal. In the
case of MAP-2 and synaptophysin staining, it was verified that the
secondary antibodies failed to produce any signal in the absence of
the primary antibodies, under the experimental conditions used.
For all epitopes, we always carried out a parallel analysis by
quantitative Western blot analysis, to confirm the trends observed
in this semi-quantitative immunohistochemistry analysis.
Statistics
Results are mean6SEM of n independent animals and
significance was considered at P,0.05 using one- or two-way
ANOVA followed by the Bonferroni or Newman-Keuls post-hoc
tests.
Results
Caffeine Attenuated Diabetes-induced Modifications of
Body Weight and Glycaemia
To test if caffeine prevented hippocampal alterations induced by
diabetes, NONcNZO10/LtJ diabetic mice and control mice were
allowed access to caffeine (1 g/L) in the drinking water during
4 months, starting at 7 months of age. Caffeine intake was similar
in control and diabetic mice, which displayed similar serum
caffeine levels (Table 1) of circa 50 mM that are equivalent to these
found in Humans drinking circa 8 cups of coffee daily, i.e. a rather
high caffeine consumption [20]. Caffeine consumption reduced
the weight gain and pre-prandial glycaemia in diabetic mice but
failed to modify diabetes-associated hyperinsulinemia (Table 1).
Table 1. Characteristics of the mice involved in the study, during and/or after caffeine treatment.
Control mice Diabetic mice Diabetic mice + Caffeine Control mice + Caffeine
Caffeine intake (mg/day/kg)
month 1 101612 9168
month 2 104659 2 65
month 3 91658 7 65
month 4 86658 5 64
Serum caffeine (mM) 50.1613.8 54.8610.4
Body weight (g)
before 43.661.5 46.161.0 47.061.4 $ 41.460.7
month 1 44.961.4 50.160.9 45.761.5 43.760.9 #
month 2 48.761.4 51.161.3 46.861.2 46.761.9
month 3 50.461.7 52.561.6 47.961.2 46.661.6 #
month 4 52.962.3 53.562.2 47.561.2 # 47.761.9 #
Glycaemia (mg/dL)
month 1 138.763.6 375.0657.9 *** 249.6647.4 # 138.467.7 ###
month 2 165.666.0 396.9655.2 *** 259.9641.7 # 181.2617.8 ###
month 3 153.4611.9 357.9658.2 *** 261.4634.1 # 150.067.3 ###
month 4 162.67623.8 426.1661.9 *** 282.3622.9 #. $ 139.4611.2 ###
Serum insulin (mg/L) 6.261.2 33.4612.0 * 38.967.9 ** 13.263.9
The study included 10 mice in the control, diabetic and caffeine groups, and 9 diabetic mice treated with caffeine (1 g/L in drinking water), which were 7 months of age
at the beginning of the study. Data are mean6SEM. * P,0.05, ** P,0.01, *** P,0.001 compared to control; # P,0.05, ### P,0.001 compared to diabetic; $ P,0.05
compared to caffeine.
doi:10.1371/journal.pone.0021899.t001
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Behavioural analysis was performed before and after caffeine
treatment, at 7 and 11 months of age respectively. Since the Y-
maze test is dependent on the exploratory behaviour of mice,
locomotion was first evaluated. It was observed that spontaneous
locomotion was significantly lower in 11 months compared to 7
months old mice (F1,65=129.44, P,0.05, n=8–10); however,
neither diabetes (P.0.05) nor caffeine consumption (P.0.05)
modified locomotor activity, as indicated by similar number of
crossing and rearing events in the open-field arena test and similar
number of total entries in the Y-maze arms (data not shown).
Spontaneous alternation in the Y-maze task revealed that diabetes
reduced the performance of hippocampal-dependent memory at
11 months of age, compared to control mice (P,0.05, n=8–10;
Fig. 1). This diabetes-induced memory impairment was prevented
by caffeine consumption (P,0.05 between diabetes and diabe-
tes+caffeine; Fig. 1), which was devoid of effects in control non-
diabetic mice (P.0.05 between control and control+caffeine;
Fig. 1). Albeit the use of a single behavioural 1 day paradigm only
allows a rough estimate of short term memory performance and
do not allow determining if memory impairment results from
deficits of memory formation and/or consolidation, the data
obtained fulfils the targeted goal of supporting that a type 2
diabetic-like condition is associated with memory impairment, as
occurs in humans [2–4]; additionally, these data suggest that long-
term caffeine consumption might prevent diabetes-induced
memory impairment.
Lack of Diabetes-induced Neuronal Degeneration
Hippocampal cellular organization and degeneration were
evaluated in brain sections stained with cresyl violet and
FluoroJade-C, respectively. The qualitative evaluation of cresyl
violet staining of the Nissl bodies (Fig. 2A) together with the lack of
FluoroJade-C stained cells (data not shown) in the hippocampal
formation of the 4 animal groups, supports the lack of diabetes-
induced overt neuronal damage in the hippocampus. This was
corroborated by the lack of modification of MAP2 immunoreac-
tivity in the hippocampus of diabetic and/or caffeine-treated mice,
as assessed quantitatively by Western blot analysis (Fig. 2C) and
semi-qualitatively by immunohistochemistry (Fig. 2B).
Caffeine Attenuated Diabetes-induced Loss of Synaptic
Markers
Evidence is accumulating supporting the idea that the
deterioration of memory performance is primarily related to
synaptic dysfunction and degeneration [24,25]. Thus, we next
tested if NONcNZO10/LtJ mice displayed alterations of two
different synaptic proteins integrating the vesicular release
machinery, synaptophysin and SNAP25. Western blot analysis
(Fig. 3A,B) showed a reduction of the immunoreactivity of
synaptophysin (223.364.9%, n=6, P,0.05) and SNAP25
(228.666.5%, n=6, P,0.05) in hippocampal membranes,
indicating the occurrence of synaptic degeneration, previously
reported to occur in models of type 1 diabetes [14,15]. Caffeine
consumption attenuated the diabetes-induced decrease of SNAP25
(Fig. 3B) and synaptophysin immunoreactivity (Fig. 3A), whereas it
was devoid of effects in control mice (Fig. 3A, 3B). Thus caffeine
prevents the synaptic deterioration that occurs upon diabetes.
Semi-quantitative immunohistochemical analysis of synaptophysin
immunoreactivity (Fig. 3C) was not sensitive enough to confirm
this reduction in synaptophysin density in the hippocampus;
nevertheless, the quantification of synaptophysin immunoreactiv-
ity showed a tendency for a systematic reduction in the CA1, CA3
and dentate gyrus of diabetic compared to control or caffeine-
treated mice (Fig. 3D).
We next investigated if the memory impairment-associated
synaptotoxity present in this model of type 2 diabetes mostly
affected pre- or post-synaptic components of either glutamatergic
or GABAergic synapses. For this purpose, we evaluated by
Western blot analysis changes in the density of presynaptic
markers of glutamatergic (vGluT1) or GABAergic terminals
(vGAT) and of markers of postsynaptic glutamatergic (PSD95)
and GABAergic synapses (gephyrin). Figure 4 shows that diabetic
mice displayed a reduced immunoreactivity of vGluT1
(228.665.3%, n=5, P,0.05; Fig. 4A) and a preserved
immunoreactivity of vGAT (28.264.2%, n=5, P.0.05; Fig. 4B)
together with a lower density of PSD95 (212.163.7%, n=5,
P,0.05; Fig. 4 C) and preserved levels of gephyrin immunoreac-
tivity (3.265.1%, n=5, P.0.05; Fig. 5D). The consumption of
caffeine attenuated the diabetes-induced decrease of vGluT1
(Fig. 4A) and PSD-95 immunoreactivity (Fig. 4C), whereas caffeine
consumption failed to modify the immunoreactivity of any of these
synaptic markers in control mice (Fig. 4).
Caffeine Prevented Diabetes-induced Astrocytosis
Semi-quantitative immunohistochemistry of the astrocytic
protein GFAP revealed an increased number of GFAP-positive
cells in the hippocampus of diabetic mice compared to controls
(Fig. 5A). Accordingly, Western blot analysis showed a
57.2610.4% increase in GFAP immunoreactivity (n=5,
P,0.05) in diabetic mice compared to controls (Fig. 5B). Caffeine
consumption reduced this diabetes-induced astrogliosis (Fig. 5), as
gauged by the reduction to near control levels of GFAP
immunoreactivity and of the number of GFAP-positive cells in
the hippocampus.
Diabetes-induced Modification of the Density of
Adenosine Receptors
Caffeine is a mixed antagonist of A1R and A2AR [5]. The
density of cortical A1R is 40 times larger than that of A2AR [5];
Figure 1. Caffeine consumption prevents memory deficits
induced by diabetes. Diabetic mice (black bars) had a reduced
spontaneous alternation in the Y-maze at 11 months of age, when
compared to controls (white bars), but not if treated with caffeine (grey
bars) for 4 months (dark bars), whereas control mice consuming
caffeine (striped bars) were similar to controls. In contrast, neither
diabetes nor caffeine affected the number of crossings or rearing events
in the open-field arena or the total number of entries in the Y-maze
arms (not shown). Data are mean6SEM of n=9–10 mice in each
experimental group. *P,0.05 versus control.
doi:10.1371/journal.pone.0021899.g001
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while decreasing that of A1R, which helps explaining why the
neuroprotection afforded by caffeine is mimicked by antagonists of
A2AR but not of A1R [11]. Thus, we now tested if the density of
A1R and A2AR in the hippocampus was modified in this mouse
model of type 2 diabetes.
Binding of the A2AR antagonist
3H-SCH58261 showed that
A2AR density increased by 261643% (Fig. 6A) in diabetic
compared to control mice (n=5, P,0.05). Caffeine consumption
also up-regulated A2AR to a smaller extent (28.063.2%, n=5,
P,0.05) but attenuated the diabetes-induced marked up-regula-
tion of A2AR (Fig. 6A).
Figure 2. Lack of structural alterations in the hippocampus of diabetic mice. Diabetic NONcNZO10/LtJ mice did not present structural
alterations in the hippocampus when evaluating Nissl bodies stained with cresyl violet in the dentate gyrus (DG), CA1 and CA3 regions (A). Neither
diabetes nor caffeine consumption affected MAP2 immunoreactivity as evaluated by immunohistochemisty in CA1 area (B) and Western blot analysis
(C, n=6). In C, the immunoreactivity was normalised to that of a-tubulin in the same membranes and calculated as percentage of control. Black, grey
and striped bars represent diabetes (Diab), diabetes plus caffeine and caffeine (Caff) groups, respectively. Data in panels (A) and (B) are representative
of 4 animals per group and in panel (C) the data are mean6SEM of n=5–6 mice in each experimental group.
doi:10.1371/journal.pone.0021899.g002
Figure 3. Caffeine attenuates diabetes-induced loss of synaptic markers. Western blot analysis revealed that diabetic mice had a reduced
immunoreactivity of both synaptophysin (A) and SNAP25 (B) in hippocampal membranes when compared to controls, which was attenuated by
caffeine. The immunoreactivity of synaptic proteins was normalised to a-tubulin in the same membranes and calculated as percentage of control. The
black, grey and striped bars represent diabetes (Diab), diabetes plus caffeine and caffeine (Caff) groups, respectively. Panel C shows representative
photographs of synaptophysin immunoreactivity, which indicate a tendency (non-significant) for a reduced immunoreactivity in the 3 hippocampal
regions in diabetic compared to control mice, as quantified in panel D (% immunoreactivity of control mice). Data in panels (A), (B) and (D) are
mean6SEM of n=5 mice in each experimental group and in panel (C) the data are representative of 5 animals per group *P,0.05, ***P,0.001 versus
control.
doi:10.1371/journal.pone.0021899.g003
Caffeine, Diabetes and Memory
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3H-DPCPX showed that A1R
density decreased by 22.561.7% (Fig. 6B) in diabetic compared
to control mice (n=5, P,0.05). Caffeine consumption slightly
up-regulated A1R (11.060.7%, n=5, P,0.05) and attenuated
the diabetes-induced down-regulation of A1R (Fig. 6B). Western
blot analysis confirmed that diabetic mice display a reduced A1R
immunoreactivity (229.666.7%, n=6, P,0.05), which was
prevented by caffeine (Fig. 6C).
Diabetes-induced Modification of the Synaptic
Distribution of Adenosine Receptors
The distribution of A1R and A2AR within glutamatergic and
GABAergic nerve terminals was evaluated by immunocytochemis-
try in hippocampal purified nerve terminals (Fig. 7). The fraction of
glutamatergic markers (vGluT1/2) or GABAergic marker (vGAT)
co-localisedwithsynaptophysin(amarkerofallnerveterminals)was
not modified either by diabetes or caffeine (Fig. 7B), indicating that
therelativedensityofglutamatergicandGABAergicsynapsesinthe
hippocampus does not seem to be affected by either diabetes or
caffeine. The immunoreactivity of A1R and A2AR detected in
vGluT1/2-immunopositive terminals was similar in the 4 groups
(Fig. 7C), whereas diabetes increased the fraction of vGAT-positive
terminals endowed with either A1Ro rA 2AR immunoreactivity by
30.761.3% (P,0.05, n=4) and 17.963.9% (P,0.05, n=4),
respectively(Fig.7D).Thisdiabetes-inducedincreaseinthefraction
of GABAergic terminals equipped with adenosine receptors was
prevented by caffeine consumption (Fig. 7D). Finally, we observed
no change in the fraction of A1R-positive terminals containing
A2AR, or vice versa (Fig. 7E). This indicates that the distribution of
presynaptic A1R and A2AR in the diabetic hippocampus changes in
GABAergic rather than glutamatergic terminals.
Discussion
The use of a novel age-related animal model of type 2 diabetes,
closely mimicking different features of this condition in humans,
NONcNZO10/LtJ mice [17], suggest the presence of impaired
memory performance, as gauged using the Y maze test; this
replicates in this animal model the clinically relevant cognitive
deficits present with higher incidence in elderly patients with type
2 diabetes [2–4]. Although more detailed behavioural studies are
required to define if long term memory is also affected and if
memory deficits result from the impairment of memory formation,
consolidation or retrieval, the present study reports novel tentative
neurochemical modifications underlying this diabetic-induced
memory impairment. Thus diabetic mice also displayed a reduced
density of hippocampal synaptic proteins when compared to
controls but did not display alterations of cellular organization or
overt neuronal degeneration in the hippocampus; this was mostly
concluded based on Western blot analysis of synaptic markers and
confirmed by semi-quantitative immunohistochemistry. Thus, the
most evident neuronal modification associated with diabetes-
induced memory impairment is confined to synapses rather than
Figure 4. Diabetic mice display a selective loss of markers of glutamatergic rather that GABAergic synapses, which is prevented by
caffeine consumption. Type 2 diabetic mice displayed a lower immunoreactivity for markers of glutamatergic (vesicular glutamate transporter
type 1, vGluT1, A) rather that GABAergic nerve terminals (vesicular GABA transporter, vGAT, B), and lower immunoreactivity for post-synaptic markers
of glutamatergic (pots-synaptic density 95 kDa protein, PSD95, C) rather than GABAergic synapses (gephyrin, D), and all these differences were
blunted by caffeine consumption. Open bars represent control mice (CTR), black bars represent diabetic mice (Diab), grey bars represent diabetic
mice consuming caffeine (Diab+Caff) and striped bars represent control mice consuming caffeine (Caff). Data are means6SEM of hippocampal
membranes from 5 rats per group; * P,0.05 between indicated bars.
doi:10.1371/journal.pone.0021899.g004
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been proposed to be a primary and initial feature resulting from
different insidious brain insults, namely in mild cognitive
impairment [26] and Alzheimer’s disease [10,24], the neurode-
generative disorder more closely associated with memory impair-
ment; this synaptotoxicity is also an early feature of other
conditions known to also involve memory impairment, such as
Huntington’s [27] or prion’s diseases [28], HIV infection [29] or
Figure 5. Caffeine preventes astrocytosis caused by diabetes. Panel A shows representative GFAP immunoreactivity photographs of CA1, CA3
and dentate gyrus (DG) showing that diabetic mice displayed increased number of GFAP-positive cells in the hippocampus, but not when consuming
caffeine. This was quantitatively confirmed by Western blot (B). GFAP immunoreactivity was normalised to b-actin in the same membrane and
calculated as percentage of control. Black, grey and striped bars represent diabetes (Diab), diabetes plus caffeine and caffeine (Caff) groups,
respectively. Data in panels (A) and (B) are representative of 4–5 animals per group and in panel (C) the data are mean6SEM of n=5–6 mice in each
experimental group. **P,0.01 versus control.
doi:10.1371/journal.pone.0021899.g005
Figure 6. Diabetes increases A2AR density and decreases A1R density in hippocampal nerve terminals.A 2AR (A) and A1R density (B) were
measured as the specific binding of a supra-maximal concentration (6 nM) of the selective antagonists of A2AR(
3H-SCH58261) and A1R(
3H-DPCPX) in
membranes from hippocampal nerve terminals of control (open bar), diabetic (black bars), diabetic treated with caffeine (grey bar) and control
treated with caffeine (striped bars) (n=5–6). Panel (C) displays a Western blot comparing A1R immunoreactivity in control or diabetic (Diab) mice
without or with caffeine (Caff) treatment, as well as the average results of A1R immunoreactivity (% of control) in 6 such experiments. *P,0.05 versus
control.
doi:10.1371/journal.pone.0021899.g006
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rats also display a reduced density of synaptic proteins [14,15],
which could be related to the observed spatial memory deficits
[1,15]. Most interestingly, we report a selective reduction of
markers of glutamatergic synapses (vGluT1 and PSD95), whereas
markers of GABAergic synapses (vGAT and gephyrin) were not
statistically affected. This indicates selective changes of glutama-
tergic rather than GABAergic synapses, in remarkable agreement
with recent results indicating that memory-related synaptotoxicity
might occur particularly in glutamatergic terminals [19,31–33].
Furthermore, we report that the changes are more evident in
presynaptic (vGluT1) rather than post-synaptic markers (PSD95),
as occurs in other conditions affecting memory [19,32]. This
suggests that the reduced density of hippocampal synaptic
proteins, particularly of glutamatergic terminals, may contribute
to the diabetes-induced memory impairment displayed by
NONcNZO10/LtJ mice.
Apart from synaptic de-regulation, diabetes-induced memory
impairment was also accompanied by astrogliosis; this was mainly
concluded based on quantitative Western blot analysis showing an
increased GFAP immunoreactivity and was confirmed by the
semi-quantitative immunohistochemistry analysis indicating an
increased number of GFAP-positive cells in the hippocampus of
diabetic mice compared to controls. Upon neuronal damage,
astrocytes can become reactive [34] and the hippocampus of
diabetic mice displayed such astrocytic hypertrophic cell bodies
and increased processes with augmented density of GFAP.
Accordingly, it has been proposed that astrogliosis may be the
earliest brain responses to hyperglycemia [35]. Astrocytes provide
a structural, metabolic and trophic support to neurons, modulating
synaptic transmission and plasticity, and acting as sensors and
initiators of brain damage [34,36]. Furthermore, astrocytic
dysfunction has been proposed to be of prime importance in the
evolution of other brain disorders (reviewed in [37,38]). This
suggests that the observed diabetes-induced astrogliosis in the
hippocampus might also contribute for synaptic dysfunction and
hampered memory performance.
Although based on correlative analysis, this possible involve-
ment of synaptotoxicity and astrogliosis in the mechanism of
diabetes-induced memory impairment is further supported by the
main finding of the present work, i.e. that long-term caffeine
consumption prevented both diabetes-associated memory impair-
ments and diabetes-induced astrogliosis and loss of nerve terminal
markers in the hippocampus. This ability of caffeine to prevent
diabetes-induced memory deficits is paralleled by the ability of
caffeine to prevent memory deficits found in aging [39,40],
Alzheimer’s [9,21] and Parkinson’s diseases [41], early-life
convulsions [19], attention deficits and hyperactivity disorders
[42], alcohol consumption [43] and streptozotocin-induced
diabetes [15]. Overall, this suggests that caffeine is able to
interfere with mechanisms playing a key role in demises of
memory dysfunction, acting as a memory stabilizer rather than as
a memory enhancer (see [7]). The only known molecular targets
for caffeine at non-toxic concentrations are A1R and A2AR, both
antagonised by caffeine [5]. A2AR seem to be the main targets of
caffeine to prevent memory impairment since: 1) chronic noxious
insults enhance the density of A2AR while reducing that of A1R
[11], as now also observed in this model of type 2 diabetes; 2)
selective antagonists of A2AR rather than A1R mimic the beneficial
effects of caffeine on afflicted memory performance (reviewed in
[6,7]). Interestingly, A2AR antagonism not only abrogates memory
dysfunction but also affords robust neuroprotection against brain
damage in different animal models of CNS disorders [11,12], most
of which involve initial modifications of synaptic function [24,25].
This further supports the involvement of synaptotoxicity in
memory dysfunction since A2AR have a predominant synaptic
localization in the hippocampus [44], where they control
synaptotoxicity [10,15,19,45,46], which we now report to be the
Figure 7. Co-localization of A1R and A2AR in glutamatergic and GABAergic nerve terminals purified from the hippocampus. Panel (A)
exemplifies the double immunostaining performed, here determining the fraction of glutamatergic (vGluT1/2-positive) terminals (synaptophysin
immunoreactivity). The fraction of glutamatergic and GABAergic nerve terminals in the hippocampus was similar in the four experimental groups (B).
The fraction of glutamatergic terminals containing A1Rs or A2ARs was not altered (C) but diabetic mice displayed increased number of GABAergic
terminals endowed with A1Ro rA 2AR (D). The fraction of nerve terminals immunoreactive for both A1Rs and A2ARs was similar in the four animal
groups (E). White, black, grey and striped bars represent control, diabetes, diabetes plus caffeine and caffeine groups, respectively. Data are
mean6SEM of n=5–6 mice in each experimental group. *P,0.05, **P,0.01 versus control.
doi:10.1371/journal.pone.0021899.g007
Caffeine, Diabetes and Memory
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e21899most evident morphological change found in the hippocampus of
diabetic mice. These synaptic A2AR undergo a gain of function in
noxious brain conditions [11]; accordingly, we now found an over
5 times increase of the density of synaptic A2AR in the
hippocampus of diabetic mice, as was previously been found to
occur in streptozotocin-treated rats [14,15]. These A2AR were not
only located in glutamatergic but also in GABAergic nerve
terminals. Whereas the role of A2ARs in glutamatergic terminals is
in accordance with their ability to control synaptic plasticity [47],
the role of A2ARs in GABAergic terminals is still unclear but may
be related to the ability of caffeine to control the silence period of
cortical firing [48].
Albeit the hypothesis that caffeine controls diabetes-induced
memory dysfunction through stabilization of cortical synapses is
appealing based on the combined observations that dysfunction
and/or loss of nerve terminals is one of the earliest modifications
in the course of neurodegenerative diseases [7,24,25] and that
A2ARs are mostly synaptically-located [44] and control the
viability of cortical synapses [10,15,19,45,46], we also observed
that caffeine prevented diabetes-induced astrogliosis. We previ-
ously showed that A2AR are also up-regulated in glial cells in the
injured brain [49] and these astrocytic A2AR can control
glutamate uptake [50] and the release of NO or interleukins
[51–52], all effects that can impact on the function and viability of
synapses. A recent study showed a direct causal relation between
reactive astrocytosis and modifications of GABAergic transmission
leading to over-excitability in hippocampal tissue, which was
argued to have a metabolic basis [53]. A direct link between
neuron-glia metabolism and memory performance has also been
provided [54]. Furthermore, the elegant studies of Detlev Boison
in animal models of epilepsy and of ischemia have emphasised the
central role astrocytic dysfunction in controlling the extracellular
levels of adenosine (reviewed in [37]); this adds an additional
metabolic dimension to the modifications of purinergic signalling
upon brain dysfunction, which was not detailed in the present
study. Overall, the observed protective effects of caffeine against
diabetes-induced memory dysfunction appear to suggest that both
synaptic dysfunction and astrocytic deregulation are expected to
be part of the mechanism by which diabetes impacts on memory
performance. However, synaptotoxicity and astrogliosis appear to
be part of the pathogenic cascade of events of different CNS
disorders, and therefore, caffeine consumption might interfere
with initial events common to different neurodegenerative brain
disorders (see [11]), rather than representing a selective strategy to
prevent diabetes-induced memory impairment. It should also be
added that caffeine-mediated neuroprotection might also involve
other mechanisms responsible for the evolution of neurodegener-
ative disorders, such as the disruption of the blood brain barrier
and neuroinflammation. In fact, caffeine and the antagonism of
adenosine receptors has been reported to prevent neuroinflamma-
tion [55–57] and damage of the blood brain barrier [58] upon
brain insults, which prompts considering to test if these changes
are present in this animal model of type 2 diabetes and if they are
also abrogated upon caffeine consumption.
In summary, the present study provides the first systematic
description of a neuropathological phenotype displayed by new
model of type 2 diabetes, that more closely mimics the ‘‘real-life’’
condition in the human diabetic population. The MS also provides
the first demonstration that the chronic consumption of caffeine
prevents memory impairment in type 2 diabetic mice, which are
accompanied by a selective loss of presynaptic (mainly glutama-
tergic markers) and astrogliosis in the hippocampus.
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